EG BioMed at ASCO｜ZFP30 cfDNA Methylation Test Shows Strong Early Detection Performance in the Western Population

In 2025, EG BioMed presented its ZFP30-targeting cfDNA methylation blood test, the EG-Pancreatic Blood Test-E1, at the ASCO Annual Meeting. The test demonstrated promising early detection results for pancreatic cancer, particularly among the Western population.

This study builds on findings we shared at the AACR Annual Meeting 1 in April 2025, where ZFP30 and ZNF781 were identified as key tumor suppressor genes in pancreatic cancer, and their methylation abnormalities were proposed as potential early detection targets. The clinical data presented at ASCO further validated this approach’s early diagnostic potential in the Western population.

Note 1:  The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the world’s largest and most influential academic conferences in the field of oncology, attracting over 40,000 cancer specialists, medical researchers, and industry representatives each year to share the latest advances in clinical trials and cancer treatment.

Study Highlights

ZFP30 is a gene found to be aberrantly methylated in pancreatic cancer. EG BioMed developed the EG-Pancreatic Blood Test-E1, a diagnostic assay that quantitatively measures ZFP30 methylation levels in circulating cell-free DNA (cfDNA) obtained from blood samples. This study employed methylation-specific qPCR and was clinically validated in both Western and Asian populations.

As shown in Figure 1, the results demonstrated that the test performed exceptionally well in detecting early-stage pancreatic cancer, particularly in Western population. It achieved a sensitivity of 92.3%, a specificity of 96.2%, and an overall accuracy of 93.2%. The area under the ROC curve (AUC) reached 0.95, significantly outperforming traditional serum biomarkers such as CA19-9 and CEA. When applied to combined data across Western and Asian populations, the assay continued to show consistent and robust performance, with a sensitivity of 96.0%, specificity of 92.4%, and overall accuracy of 92.5%. These findings highlight the clinical potential of ZFP30 methylation as a reliable biomarker for early pancreatic cancer detection across diverse populations.

Study Summary

The ZFP30 cfDNA methylation blood test offers multiple advantages, including non-invasiveness, high diagnostic accuracy, and consistent performance across populations. Notably, the test also demonstrated strong early detection performance in Western patients with pancreatic cancer, addressing the current gap in reliable early detection tools.

EG BioMed remains committed to advancing the clinical adoption of its blood testing technology through close collaboration with medical institutions, aiming to enable earlier and more accurate diagnosis for high-risk individuals, improve treatment effectiveness, and enhance patient outcomes.

🔗 View Abstract on ASCO Website: https://meetings.asco.org/abstracts-presentations/251068